CTIC News 2.86 06/30/2014 04:39:10 Cell Therapeutics (CTIC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 2.86 $CTIC

Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics
PR Newswire - Fri Jun 27, 6:00AM CDT
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average declined 0.13%, to finish the day at 16,846.13, and the S&P 500 closed at 1,957.22, down 0.12%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, with the index also advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corp. (NASDAQ: CTIC), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free technical research on CTIC, BMRN, VRTX and NWBO can be downloaded upon signing up at:

Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - Fri Jun 13, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.

CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS
PR Newswire - Thu Jun 12, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. The trial is being conducted by the National Cancer Research Institute Haematological Oncology Study Group under the sponsorship of Cardiff University. The trial management group is led by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University. Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.

Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders
at The Street - Mon Jun 09, 9:16AM CDT
Stocks with insider trader activity include MWE, CPT and CTIC

Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.

Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.

CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.

Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.

Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:

Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.

Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....

Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).

Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.

Zack's Research Initiates Coverage on Theralase With a Price Target of $1.00
ACCESSWIRE - Tue May 20, 9:22AM CDT
Theralase Lights Up Cancer Therapeutics

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:

Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.

PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -

PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 87

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 108

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 94

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 70

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 188

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 77

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Smart Mattress Market Expected to Reach USD 2.3 Billion Soon

Updated Category News Views 231

Overview of the Smart Mattress Market Growth Smart mattresses have emerged as key players in the bedding industry, shaped by the rising awareness of sleep's importance to overall health. With a current valuation of approximately USD 1.6 billion in 2023, the market is projected to reach USD 2.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 3.7% in the...

Continue Reading
VyStar Foundation Celebrates Investment in Kennesaw State Education

Updated Category News Views 178

VyStar Credit Union and Kennesaw State Unveil VyStar Arena The anticipation surrounding the recent unveiling of VyStar Arena at Kennesaw State University is palpable, marking a significant achievement for both the university and VyStar Credit Union. This newly renovated arena will serve as the heart of athletic activities, hosting women's volleyball and men's basketball...

Continue Reading
Google Cloud and Verizon Transform Customer Engagement with AI

Updated Category News Views 599

Google Cloud and Verizon: Pioneering Customer Experience Innovations In a groundbreaking collaboration, Google Cloud has joined forces with Verizon to revolutionize customer service through innovative technology. This partnership leverages Google Cloud's generative AI to enhance the way Verizon serves its customers, resulting in significant improvements in customer...

Continue Reading
Celebrating the Holidays: Joyful Activities for Seniors

Updated Category News Views 161

Bringing Festive Cheer to Seniors This Holiday Season The holiday season is a special time for celebration, togetherness, and creating lasting memories, particularly for our seniors. Executive Home Care is dedicated to enhancing the holiday spirit for seniors by encouraging families and caregivers to engage in joyful activities that uplift and connect the loved ones in...

Continue Reading
Paragon Sports Revolution: NYC Store's Bold Overhaul

Updated Category News Views 32

Paragon Sports Redefines NYC's Retail Scene If you're thinking classic old guard can't innovate, take a gander at Paragon Sports. This 118-year-old New York cornerstone isn't just resting on its laurels as some ancient relic; they're breaking out the playbook for a fresh start in the Big Apple. In a bold move, they’ve decided to not only enhance their in-store...

Continue Reading